Shares of Knight Therapeutics Inc. (TSE:GUD – Get Free Report) fell 0.2% on Monday . The stock traded as low as C$5.65 and last traded at C$5.70. 36,840 shares changed hands during trading, a decline of 37% from the average session volume of 58,048 shares. The stock had previously closed at C$5.71.
Wall Street Analysts Forecast Growth
Separately, Raymond James raised Knight Therapeutics to a “moderate buy” rating in a research report on Friday, November 15th.
Read Our Latest Research Report on GUD
Knight Therapeutics Price Performance
Insider Activity at Knight Therapeutics
In related news, Director Samira Sakhia purchased 20,000 shares of the stock in a transaction on Monday, November 11th. The shares were purchased at an average cost of C$5.15 per share, with a total value of C$103,000.00. Also, insider Sime Armoyan bought 90,300 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were purchased at an average cost of C$5.13 per share, with a total value of C$463,672.44. 45.62% of the stock is owned by insiders.
Knight Therapeutics Company Profile
Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.
Featured Articles
- Five stocks we like better than Knight Therapeutics
- What Are Dividends? Buy the Best Dividend Stocks
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- What Are the FAANG Stocks and Are They Good Investments?
- 3 Steel Stocks Soaring After Tariff Announcements
- What is a Dividend King?
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.